Artículos por temáticas

Elevated serum TC and LDL-C levels in Alzheimer's disease and mild cognitive impairment: A meta-analysis study

Liu Y, Zhong X, Shen J, Jiao L, Tong J, Zhao W, Du K, Gong S, Liu M, Wei M.

Brain Res. 2020 Jan 15;1727:146554. doi: 10.1016/j.brainres.2019.146554. Epub 2019 Nov 23.

Multifarious roles of mTOR signaling in cognitive aging and cerebrovascular dysfunction of Alzheimer's disease

Uddin MS, Rahman MA, Kabir MT, Behl T, Mathew B, Perveen A, Barreto GE, Bin-Jumah MN, Abdel-Daim MM, Ashraf GM.

IUBMB Life. 2020 Sep;72(9):1843-1855. doi: 10.1002/iub.2324. Epub 2020 May 30.

Is There a Future for PPARs in the Treatment of Neuropsychiatric Disorders?

Tufano M, Pinna G.

Molecules. 2020 Feb 27;25(5):1062. doi: 10.3390/molecules25051062.

Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease

Vander Zanden CM, Chi EY.

J Pharm Sci. 2020 Jan;109(1):68-73. doi: 10.1016/j.xphs.2019.10.024. Epub 2019 Oct 21.

ATP synthase and Alzheimer's disease: putting a spin on the mitochondrial hypothesis

Ebanks B, Ingram TL, Chakrabarti L.

Aging (Albany NY). 2020 Aug 27;12(16):16647-16662. doi: 10.18632/aging.103867. Epub 2020 Aug 27.

An Updated Review: Androgens and Cognitive Impairment in Older Men

Cai Z, Li H.

Front Endocrinol (Lausanne). 2020 Nov 13;11:586909. doi: 10.3389/fendo.2020.586909. eCollection 2020.

Status and future directions of clinical trials in Alzheimer's disease

Plascencia-Villa G, Perry G.

Int Rev Neurobiol. 2020;154:3-50. doi: 10.1016/bs.irn.2020.03.022. Epub 2020 Jul 20.

PPARα serves as a new receptor of aspirin for neuroprotection

Patel D, Roy A, Pahan K.

J Neurosci Res. 2020 Apr;98(4):626-631. doi: 10.1002/jnr.24561. Epub 2019 Dec 3.

In Vitro and In Vivo Comparison of Curcumin-Encapsulated Chitosan-Coated Poly(lactic-co-glycolic acid) Nanoparticles and Curcumin/Hydroxypropyl-β-Cyclodextrin Inclusion Complexes Administered Intranasally as Therapeutic Strategies for Alzheimer's Disease

Zhang L, Yang S, Wong LR, Xie H, Ho PC.

Mol Pharm. 2020 Nov 2;17(11):4256-4269. doi: 10.1021/acs.molpharmaceut.0c00675. Epub 2020 Oct 21.

Epigenetic Basis of Lead-Induced Neurological Disorders

Wang T, Zhang J, Xu Y.

Int J Environ Res Public Health. 2020 Jul 7;17(13):4878. doi: 10.3390/ijerph17134878.

Cerebral small vessel disease genomics and its implications across the lifespan

Sargurupremraj M, Suzuki H, Jian X, Sarnowski C, Evans TE, Bis JC, Eiriksdottir G, Sakaue S, Terzikhan N, Habes M, Zhao W, Armstrong NJ, Hofer E, Yanek LR, Hagenaars SP, Kumar RB, van den Akker EB, Mc

Nat Commun. 2020 Dec 8;11(1):6285. doi: 10.1038/s41467-020-19111-2.

Mitochondrial Dysfunctions: A Red Thread across Neurodegenerative Diseases

Stanga S, Caretto A, Boido M, Vercelli A.

Int J Mol Sci. 2020 May 25;21(10):3719. doi: 10.3390/ijms21103719.

Application of Contemporary Neuroproteomic Techniques in Unravelling Neurological Disorders

Khurana M, Rahman SO, Najmi AK, Pottoo FH, Akhtar MS.

Curr Protein Pept Sci. 2020;21(12):1146-1163. doi: 10.2174/1389203721666201104130135.

The Role of Chemokines in Alzheimer's Disease

Jorda A, Campos-Campos J, Iradi A, Aldasoro M, Aldasoro C, Vila JM, Valles SL.

Endocr Metab Immune Disord Drug Targets. 2020;20(9):1383-1390. doi: 10.2174/1871530320666200131110744.

Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic brain injury, and related brain disorders

Hook V, Yoon M, Mosier C, Ito G, Podvin S, Head BP, Rissman R, O'Donoghue AJ, Hook G.

Biochim Biophys Acta Proteins Proteom. 2020 Aug;1868(8):140428. doi: 10.1016/j.bbapap.2020.140428. Epub 2020 Apr 17.